IL-6 receptor inhibition and risk of sarcoidosis: a Mendelian randomization study

Rheumatology (Oxford). 2024 Apr 2;63(4):e118-e119. doi: 10.1093/rheumatology/kead613.

Authors

Sizheng Steven Zhao¹, Matthew C Baker², James B Galloway³

Affiliations

¹ Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal and Dermatological Science, School of Biological Sciences, Faculty of Biological Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
² Division of Immunology and Rheumatology, Department of Medicine, Stanford University, Stanford, CA, USA.
³ Centre for Rheumatic Diseases, King's College London, London, UK.

No abstract available

MeSH terms

Genetic Predisposition to Disease
Genome-Wide Association Study
Humans
Mendelian Randomization Analysis*
Polymorphism, Single Nucleotide
Receptors, Interleukin-6 / genetics
Risk Factors
Sarcoidosis* / genetics

Substances

Receptors, Interleukin-6

Grants and funding

21173/VAC_/Versus Arthritis/United Kingdom